相反，关键是要瞄准有品牌的仿制药。
它允许通过仿制药竞争以降低价格。
难怪仿制药公司越来越有信心。
这可以加快涉足品牌仿制药。
一些制药公司则走的更远：收购仿制药竞争对手。
Several pharmaceutical companies have gone further and bought generic-making rivals.
“仿制药公司需要更加灵活精干和积极进取”，他说。
"Generics firms need to be nimble and aggressive," he observes.
大制药公司指出，授权的仿制药能够压低仿制品的价格。
The big drug firms point out that authorised generics drive down the price of copies.
它的六种主要产品由五种将在今后四年面临仿制药的竞争。
Five of its six leading products face generic competition in the next four years.
第二，仿制药生产商不断合并，每种药物的生产商通常只有一两个公司。
Second, generic drugmakers have merged, so a given drug is often made by just one or two companies.
但拥有专利的罗氏药物公司不希望穷国为本国生产廉价仿制药。
But Roche — the drug company that owns the patent — doesn't want the poor world making cheaper copies for themselves.
首先在发达国家，2010年富裕国家将以两种方式促使仿制药增加财富。
First, the developed world. In 2010 rich countries will boost the fortunes of generic drugs in two ways.
综上所述，以上趋势表明，2010年将是全球仿制药产业的转折点。
Taken together, these trends point to 2010 being a turning-point for the global generics business.
梯瓦公司是世界上最大的仿制药制造公司，但是过去并没有注意自由品牌的开发。
Teva is the world's largest generic drug maker but hasn't focused on private-label branded products in the past.
尽管中国具有增长潜力，但主要生产仿制药的国内企业，仍占据约四分之三的市场。
In spite of China's growth potential, local companies, which mainly produce generic drugs, still account for about three quarters of the market.
一旦某种药物失去专利保护，仿制药生产商就会一拥而上争夺市场份额，导致价格暴跌。
After a drug loses its patent protection, its price plunges as generic drugmakers fight for market share.
而这种繁荣还要继续，美国仿制药部门预测，到2012年还将有超过9%的增长。
And the boom is set to continue, with the American generics sector forecast to grow by over 9% a year to 2012.
但他也表示，这次他非常谨慎地看待新仿制药物的前景，因为生物技术药物很难仿制。
But he also said he was more cautious about the promise of generics this time, because biotech medicines were not easy to copy.
报告指出，在许多国家，如果采用鼓励使用仿制药政策，可以节省大约60%的药费。
As the report notes, a policy that encourages the use of generic medicines could save around 60% of the costs of medicines in many countries.
报告指出，在许多国家，如果采用鼓励使用仿制药政策，可以节省大约60%的药费。
As the report notes, a policy that encourages the use of generic medicines could save around 60% of the costs of medicines in many countries.
应用推荐